Dihexa
Rat studies from one lab; no human studies.
A lab-made compound from one university group, promoted online as a powerful memory enhancer on the strength of rat studies. has found no record of it ever being given to people in a study. A , also called PNB-0408.
What the evidence shows
Side effects and risks
Who should avoid it: Everyone.
How it works
- Where it acts
- It binds HGF, a growth factor, and boosts its signalling through the MET receptor.
- What it changes
- In rats, more connections between nerve cells and better memory.
- What people notice
- No human studies. MET signalling also drives some cancers, a theoretical risk.
How it has been given in studies
No human dose exists.
Getting it in the United States
The legal route for Dihexa
Not FDA-approved. FDA advisers have reviewed, or are due to review, whether pharmacies may compound it. Until FDA acts, there is no lawful route. Vials sold for research use are unapproved drugs when marketed for people.
Routes people use for any peptide in the United States
Telehealth prescribing
Online clinics prescribe after a questionnaire, sometimes with no live doctor visit, and mail the drug. FDA moved in February 2026 to restrict mass-marketed compounded copies and claims that they are generic equivalents.
Risk: Thin medical screening. Compounded versions are not reviewed by FDA for quality.
Covers: Approved GLP-1 drugs, compounded semaglutide and tirzepatide
Source: GZERO Media, Apr 2026
Clinical trial enrolment
The only lawful way to get an unapproved peptide drug with medical monitoring. ClinicalTrials.gov lists eligibility, sites and phone numbers. Researchers note recruitment is hard when people can buy the drug on the gray market instead of risking placebo.
Risk: Possible placebo assignment, strict eligibility and travel to a study site.
Covers: Investigational peptide drugs still in development
Source: NIH, finding a clinical trial
Compounding pharmacies
FDA took dihexa acetate off its Category 2 safety-concern list in 2026-04. Lawyers say that does not make it eligible for compounding. An advisory committee review is due before 2027-02.
Source: Frier Levitt, 2026
Routes people use for any peptide in the United States
Compounding pharmacy with prescription
A clinician prescribes and a pharmacy compounds. Twelve peptides left the FDA do-not-compound category in April 2026 and a panel backed six in July, but they are not yet formally eligible. Pharmaceutical-grade ingredient is scarce.
Risk: Legal status is unsettled until FDA rulemaking ends. Pharmacies may use research-grade ingredient.
Covers: BPC-157, TB-500, KPV, MOTS-c, Semax, Epitalon and similar
Source: Frier Levitt, Apr 2026
Med spas and weight-loss clinics
Very common. Secret shoppers called 75 clinics and med spas in two states after shortages ended. 92 percent offered compounded semaglutide and 87 percent tirzepatide, often mixed with B vitamins to look custom.
Risk: Four of 23 suppliers lacked sterile compounding licenses and four had disciplinary records.
Covers: Compounded semaglutide and tirzepatide
Source: American Med Spa Association on JAMA Health Forum study, Jul 2026
Concierge and longevity doctors
Cash-pay physicians build peptide plans for wealthy clients. Reporting from San Francisco says some source from overseas channels, domestic research-use-only sellers or the few compounding pharmacies that will supply clinicians.
Risk: A doctor's involvement does not guarantee a pharmaceutical-grade product.
Covers: BPC-157, thymosin alpha-1, Selank, Semax, CJC-1295, ipamorelin, retatrutide
Source: San Francisco Standard, Sep 2025
Cross-border purchase or import
FDA says importing drugs for personal use is illegal in most cases but it may not object to small personal quantities in limited situations. Reporting also describes people travelling to Mexico for injections.
Risk: Packages can be seized. Product origin and cold-chain handling are hard to check.
Covers: Approved prescription peptides sold abroad
Source: FDA, personal importation
Research-grade raw material
Lawyers note pharmaceutical-grade ingredient may not exist at commercial scale and research-grade ingredient cannot lawfully be used in compounding. FDA says it knows of no human exposure data, so buyers have no safety baseline.
Source: Frier Levitt, 2026
Routes people use for any peptide in the United States
Research-chemical websites
Sites sell vials marked for research or not for human consumption, with no prescription. FDA says some ship direct to consumers with dosing directions, and it has sent warning letters. Retatrutide exists only through this route or trials.
Risk: Unknown identity, strength and sterility. No pharmacist or prescriber involved.
Covers: Retatrutide, semaglutide, tirzepatide, BPC-157 and most unapproved peptides
Source: FDA, unapproved GLP-1 drugs page
Direct orders from Chinese factories
Buyers message factory sales agents and pay by crypto or payment app. A minimum order of about ten vials pushes people to buy in bulk and share. A blockchain analysis found US buyers were the largest source of funds.
Risk: Many of the same vendors list fentanyl precursors. Lab reports sent by sellers cannot be verified.
Covers: GLP-1 copies, melanotan II, BPC-157, TB-500, GHK-Cu, epitalon
Source: TRM Labs, Oct 2026
Chat groups and social sellers
Dealers are found through Telegram, WhatsApp, Discord and influencer discount codes. In a May 2026 survey of 1,000 US users, 14.5 percent bought this way and three quarters asked an AI chatbot for dosing.
Risk: 45 percent of social media buyers in that survey reported an emergency or urgent care visit for a reaction.
Covers: Retatrutide and other research-use-only peptides
Source: The Ethos, May 2026
This describes what people do. It is not advice. The decision is yours.
What users report
Recurring themes in public forum posts, unverified and with no comparison group.
Reported benefits
- Better recall and verbal fluency
Reported problems
- Headache, irritability
- Worry about long-term risk
Self-reported memory gains are unreliable without testing.
More contextWhat public figures say, videos and articles, when options run out and the chemistry
What experts and influencers say
Paraphrased from the linked sources.
Calls the craze unfounded. He found no randomized human trial showing the advertised benefits for any of the unapproved peptides he reviewed, and warns about stacking several at once. He points to animal work in which TB-500 sped up dormant tumor growth and to a theoretical cancer concern with growth-hormone peptides and BPC-157. He treats the GLP-1 drugs as the well-studied exception.
Source: Eric Topol, "The Peptide Craze", Jul 2025, Associated Press, Nov 2025
Eric TopolWebsiteWarns against
His team developed dihexa. A patent in his name claims short safety studies showed no apparent toxicity and no tumour induction. The encyclopedia entry flags the tumour claim as lacking a citation.
Source: Wikipedia, Dihexa, 2013-12
Joseph HardingSourceRecommends
Money: Named inventor on dihexa patents
Paid a 4 million dollar settlement in 2025 over allegations that its former chief executive falsified research used to win a federal grant, per reporting cited in the company's encyclopedia entry.
Source: Wikipedia, Athira Pharma, 2025
Athira PharmaSourceMixed view
Money: Company built on the dihexa research line
States it lacks important safety information on dihexa acetate and has found no human exposure data.
US Food and Drug AdministrationSourceWarns against
Watch and read
Explainers, reporting and podcasts worth your time. Summaries are ours. No sellers.
Prospective Alzheimer's drug builds new brain cell connections, improves cognitive function of rats
Washington State University
WSU researchers report dihexa improved memory and learning in rats with Alzheimer's-like impairment by rebuilding connections between nerve cells. Animal data only.
Original university news on the rat research
Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks
FDA
FDA says it has no human exposure data for dihexa acetate by any route and lacks key safety information.
Regulator warning: no human safety data
When options run out
Uses people turn to when standard treatment has failed.
Dementia, through a related trial drug
- Who
- People with Alzheimer's or Parkinson's dementia who join company trials of fosgonimeton, a compound Alzforum links to dihexa.
- Evidence
- Phase 1 in 88 people raised no safety issues and showed brain-wave changes. It had no cognitive measures. No human data exist for dihexa itself.
- Route
- Company-run phase 2 trials of fosgonimeton
Legal last-resort routes
Expanded access (compassionate use)
For a serious or life-threatening condition with no comparable alternative and no trial you can join. Your physician asks the company for the drug, then files with FDA and an ethics board. The company can refuse. Costs are often not insured.
Right to Try
For a life-threatening condition after approved options are exhausted and no trial is open to you. The drug must have finished Phase 1 and be in active development. Your doctor asks the manufacturer directly. FDA does not review requests.
Source: FDA, Right to Try
Trial finders
Search ClinicalTrials.gov by condition or drug name, check eligibility and call the listed site. ResearchMatch is a free NIH-funded registry that lets researchers find you. Discuss risks with your own clinician before enrolling.
Source: NIH, finding a clinical trial
Personal import for serious conditions
FDA may not object when a US citizen imports up to about three months of a drug for a serious condition with no effective US treatment, with written personal-use confirmation and a US doctor's details. It is discretion, not a right.
Source: FDA, personal importation
Patient-specific compounding
When the approved product cannot meet a specific need of an identified patient, a prescriber can order a compounded version from a licensed pharmacy. Lower price alone does not qualify. Ingredients must be pharmaceutical grade.
Amino-acid sequence
Ringed tiles are amino acids not found in natural proteins.
Questions people ask
Does Dihexa improve memory?
Only rat and cell studies from a single lab support it, and four related papers from that lab carry journal notices about possible image manipulation. There are no human studies.
Is Dihexa safe?
There are no human safety data of any kind. It is reported to act through a growth pathway (HGF and c-Met) that is also active in many cancers, a theoretical risk.
What is FDA doing about Dihexa?
FDA advisers are due to review it for compounding by February 2027. FDA has found no record of it ever being given to people in a study.
Your notebook
Taking it? A ten-second daily check-in keeps a record of how you feel, to talk through with your clinician.
Sources
- FDA: bulk substances that may present significant safety risks
- Retraction Watch: four papers earn expressions of concern (Sep 2021)
- Retraction Watch: settlement over data-falsification allegations (Jan 2025)
Structure: PubChem